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Abstract CCR5 expression on CD4+CD25highFoxp3+ regulatory T cells (Tregs) has been reported to
be crucial for limiting Th1 inflammation associated with autoimmunity and bacterial infections.
We inquired whether abnormalities in chemokine receptors expressed on Tregs might be involved in
the psoriatic pathogenesis. Indeed, the proportion of CCR5+ Treg was 58.8% in healthy individuals
(n = 9), whereas only half as many CCR5+ Treg cells were found in psoriatic individuals (29.1%, n = 8,
p b 0.01). The flow-enriched control CCR5+ Tregs consistently exceeded the suppressive capacity of
unsorted Tregs in autologous MLR assays (n = 5, p b 0.05) showing that CCR5+ Treg subset is a high
potency regulatory T cell population. Interestingly, psoriatic CCR5+ Treg cells exhibited significantly
less migratory capacity toward CCR5 ligands MIP-1β and RANTES in vitro compared to CCR5+ Treg
controls (n = 3, p b 0.05). Our data demonstrate that psoriatic CCR5+ Tregs cells are numerically-,
functionally- and chemotactically-deficient compared to controls and may pose a triple impairment
on the ability of psoriatic Tregs to restrain inflammation.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.upport: National Institutes of
DC).
Western Reserve University,
.D. Cooper).
y to this work.
ed by Elsevier Inc.
3.06.007
Open access Health (P30AR039750, P50AR055508; R01AR051498 KDC), Murdough
Department of Dermatology, BRB531, 10900 Euclid Ave, Cleveland, OH
under CC BY-NC-ND license.
112 D.C. Soler et al.1. Introduction
Human regulatory T cells (Tregs) are considered the immune
system guardians against development of autoimmune
disorders, being responsible for maintaining self-tolerance
and playing an important role in limiting autoreactive and
pathogenic cells. Tregs were initially characterized by
expression of CD4 and high expression of the interleukin
(IL)-2 receptor [alpha]-chain (CD25) [1]. Subsequent to
this description, expression of the transcription factor
Forkhead box P3 (Foxp3+) was described to be the master
transcriptional regulator of Tregs [2], with a concomitant
lack of expression of the Interleukin-7 receptor subunit
alpha (IL7R-α or CD127) [3]. Murine confirmation of the
Treg master transcription factor Foxp3 was demonstrated
when the mutation resembled human patients with
immune dysregulation, polyendocrinopathy, enteropathy
and X-linked syndrome (IPEX), diseases which carry a direct
link to Foxp3 [4,5].
Recently, several studies have demonstrated that various
chemokine receptors including CC chemokine receptor 5
(CCR5) are constitutively expressed on Tregs in humans
and likely provide Tregs with a competitive advantage
over naive T cells to migrate more efficiently to the
periphery [6–9]. In addition to regulatory cell trafficking
CCR5 also participates in control of effector functions of
memory/effector T lymphocytes, macrophages, and imma-
ture dendritic cells (DCs). CCR5 is a G-Protein Coupled
Receptor (GPCR) that binds the chemokines CCL5 (RANTES),
CCL3 (MIP-1α) and CCL4 (MIP-1β) and is expressed on
effector T cells that home toward peripheral sites of
inflammation [10]. Deficiency in CCR5 leads to a reduced
T cell infiltration in parasitic infections such as Trypanosoma
cruzi [11,12] and Toxoplasma gondii [13], as well as viral
infections [13].
Several human autoimmune diseases exhibit a dysregulated
T cell response in which the activity of pathogenic effector T
cells (Teff) is inadequately controlled by naturally occurring
CD4+CD25high Foxp3+ CD127− Tregs [14,15]. In those cases,
functional defects appear in Teff as well as Treg populations
which lead to a loss of tolerance and subsequent activation and
differentiation of pathogenic Th1 and Th17 cells [16,17].
Psoriatic Tregs are deficient in suppressing not only
autoimmune Teffs but also normal (healthy) Teffs as
shown in previous “criss-cross experiments” [18]. We also
previously demonstrated that, as shown in the mouse [19]
IL-6 could reverse the function of healthy human Tregs [20]
Interleukin-6, which is highly elevated in psoriatic tissue,
was demonstrated to induce Stat3 signaling prior to
subsequent T cell activation, which results in the loss of
functional Treg suppression [21]. However, the underlying
mechanisms responsible for the suboptimal suppressive
activity of psoriatic Treg remain incompletely defined.
Recently CCR5 expression has been shown to be important
for high potency Treg cells in a mouse model [22].
In the current manuscript, we show that the presence of the
chemokine receptor CCR5 on the surface of regulatory T cells is
associated with Tregs that exhibit enhancement of their
suppressive potential in vitro. Indeed, Treg cells with higher
CCR5 expression are superior suppressors of activated Teff cells
and exhibit higher levels of the transcription factor Foxp3 as
measured by flow cytometry and real-time PCR. Unfortunatelyfor psoriasis patients CCR5 expression on Tregs is decreased
compared to healthy controls, leading to a reduction in the
CCR5+Foxp3high high potency Treg population. Chemotaxis
assays confirmed that CCR5+ Tregs isolated from healthy
controls display superior migration toward the CCR5 ligands
MIP1β and RANTES compared to CCR5+ Tregs from psoriasis
patients. These results suggest that impaired CCR5 likely
contributes to the long-term failure of psoriatic Tregs to
competently suppress the expanding effector cell response.
2. Materials and methods
2.1. Cell isolation and culture of human dermal cells
and PBMCs
All studies involving human subjects were approved by
the Institutional Review Boards of Case Western Reserve
University and University Hospitals Case Medical Center.
Punch biopsies and/or peripheral blood samples were
obtained from healthy adult volunteers or patients with
moderate plaque psoriasis following informed consent.
Primary dermal cells were isolated as previously described
[23] and cultured in complete medium (RPMI 1640 containing
10% FBS (Cambrex), L-glutamine, penicillin, streptomycin
and 2 ME (Cellgro)). PBMCs were prepared from peripheral
blood as previously described [18] and adhered to plastic for
1 h to enrich for the non-adherent, lymphocyte-containing
fraction. Dermal cell suspensions were prepared from
lesional skin biopsies as described previously, with minor
modifications [23]. The DNCB exposure in psoriatic patients
was a one-time pilot observational experiment. Viability
was determined by trypan blue exclusion (70–90% range);
CD4+ cells were separated from PBMC's by negative
selection on midiMACS columns (CD4+ T cell isolation kit;
Miltenyi Biotec) according to the manufacturer's instruc-
tions. After over-night incubation, CD4+CD25high (top 5%)
CCR5+ cells were sorted using a BD FACS Aria flow cytometer
and FoxP3 was analyzed.
2.2. Proliferation assays
CD4+CD25− Teff, 2 × 104 cells were cultured 6–7 days in
round-bottom, 96-well plates (Costar) in the presence or
absence of various dilutions of Treg cells. 1 × 105 plastic-
adherent 3000-rad irradiated PBMCs were used as APCs
per well. Cells were pulsed with 1 μCi/well [3H] thymi-
dine for the last 16 h before harvesting on the day
described.
2.3. Antibodies and flow cytometry
Surface markers on blood or skin cells were detected
by incubation with CD4-APC and CD25-PE monoclonal
antibodies (mAbs) (BD), followed by fixation in 4%
paraformaldehyde. To detect intracellular antigens, cells
were permeabilized using a perm/fix kit (BD Biosciences).
Analytical samples were analyzed on a BD LSR II flow
cytometer (BD Biosciences). The following chemokine
receptor mAbs were used for analyzing sorted Tregs:
anti-CD62L-PECy5, anti-CLA-FITC, anti-CCR4-Pecy7, anti-
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APC, anti-CXCR3-PEcy5, anti-CXCR4-PEcy5, anti-CXCR5-
APC, anti-CXCR6-APC, anti-β7-integrin-APC (all R&D).
2.4. Real-time quantitative RT-PCR
Total RNA was extracted from CD4+CD25high top 5% Treg
of healthy and psoriatic volunteers using an RNeasy mini
kit (Qiagen). RNA was reverse transcribed using 200 U of
Moloney murine leukemia virus (MMLV) reverse transcriptase
(Invitrogen Life Technologies) according to the manufacturer's
instructions. cDNA was amplified in the presence of specific
primers and probes for Foxp3 or 18S rRNA and TaqMan Universal
Master Mix in a 96-well microtiter plate format on an Abi PRISM
7700 Sequence Detection System (all from Applied Biosystems).
Each PCR was performed in triplicate, using the following
conditions: 2 min at 50 °C and 10 min at 95 °C, followed by
40 cycles of 15 s at 95 °C and 1 min at 60 °C. Copy numbers of
samples were calculated against input copy numbers of plasmid
standards for both target and 18S rRNA genes and were
normalized with the copy numbers of the 18S rRNA gene.
2.5. Regulatory T cells chemotaxis assay
Chemotaxis using transwell plates (pore size, 5 μm) was
conducted in vitro, and the migratory capacity of control
and psoriatic CCR5+ Treg cells toward the CCR5 relevant
chemokines MIP-1β and RANTES was measured. 1 × 105
CCR5+ peripheral Tregs from psoriatic patients or healthy
donors were loaded onto the upper transwell plates. TheFigure 1 Reduction of CCR5 positive regulatory T cells in patients
on both control and psoriatic regulatory T cells (Treg). CD4+ (n
CD25highFoxP3+ Treg cells were gated and analyzed further for ex
events/chemokine). CCR5 expression was significantly decreased by
Treg cells (p b 0.01). No significant expression differences were obsaverage number of CCR5+ Treg cells isolated from healthy
controls that migrated toward MIP-1β or RANTES was
counted and the averages were expressed as the ratio
(chemotactic index) of the number of cells in the treated
sample versus control (spontaneous migration).
2.6. Statistical analysis
Statistical analysis was performed using Student's t test. A
value of p b 0.05 was considered significant.3. Results
3.1. Expression levels of various chemokine receptors
on normal and psoriatic CD4+CD25high and Foxp3+
Tregs from peripheral blood
We previously demonstrated that regulatory T cells isolated
from psoriatic patients exhibited a decreased capacity to
suppress expanding effector T cell population in allo-MLR assays
compared to healthy controls [18]. In order to characterize the
possible mechanisms responsible for the previously observed
decrease in psoriatic Treg suppressive capacity, we compared
CD4+CD25high Foxp3-expressing Tregs isolated from healthy
controls and psoriatic patients for the expression of several
common immunological surface receptors including CD62L,
CLA, CCR5, CCR4, CCR6, CCR7, CCR8, CXCR3, CXCR4, CXCR5,
CXCR6 and β7-integrin. Primarily, expression of CCR5 appears
decreased on psoriatic patient Tregs (29.1 ± 3.0%, n = 8)with psoriasis. Expression levels of various chemokine receptors
egative bead selection) T cells defined by CD25 and FoxP3.
pression of the indicated chemokine receptors (3000 positive
50% in psoriatic (n = 8) Treg cells compared to control (n = 9)
erved on other chemokine receptors investigated.
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contrast, no statistically significant expression differences were
observed among the several other chemokine receptors
examined. Interestingly, Treg surface markers are increased in
CCR5+ Tregs (Supplemental Fig. S1) and the CCR5 MFI of
psoriasis patients is approximately one-half of control individ-
uals (Supplemental Fig. S2).3.2. The CCR5+ Treg subset exhibits higher Foxp3
expression and functional suppressive activity
To determine whether diminished CCR5 expression on Tregs
may mark a functionally impaired subset, we examined
the levels of Foxp3 expression in CCR5+ Tregs by flow cytometry
and quantitative PCR. Total RNA from sorted CCR5+ Tregs
(n = 3) was reverse transcribed and amplified in the presence of
primers specific for Foxp3 and 18S ribosomal RNA. Unsorted
Tregs showed statistically significant lower levels of Foxp3
mRNA expression compared to CCR5+ Tregs (Fig. 2A).
Furthermore, intracellular flow cytometry on control
CD4+CD25high (top 5%) Tregs appear to show that the CCR5+
subset of Tregs also expresses higher levels of Foxp3 (MFI 45.2).
By contrast, the expression of another chemokine receptor,
CXCR3 (MFI 51.4), in Tregs showed no relative increase in Foxp3
(Fig. 2B).
We next examined the functional suppressive capacity of
CCR5+ Tregs versus a pool of unsorted CD4+CD25high Tregs.
CCR5-expressing Tregs demonstrated a higher suppressive
capacity compared to the unsorted Treg pool. Shown for
comparison is a representative Treg from a non-psoriatic
individual (Fig. 3A, shown as individual cpm values compared to
a Treg pool from the same individual) as well as cumulative data
from five separate individuals (Fig. 3B, shown as reduction in
percentage suppression).
Interestingly, CCR5+ Treg populations showed an increased
percentage of CTLA4, CD120b and GITR expression compared
to CCR5− Treg populations based upon isotype (SupplementalFigure 2 CCR5 positive Treg cells express higher levels of mRNA
statistically significant higher mRNA FoxP3 expression level of CCR5+
cells. In agreement, CCR5− Treg cells showed significantly less FoxP3
CD4+ T cells were analyzed for CD25 expression, and cells with the hig
were further defined by [FoxP3 and CCR5] (left) and [FoxP3 and CX
higher Foxp3 levels, whereas the expression of another chemokine re
Foxp3.Fig. S1, two controls and two psoriatic samples are shown).
However, the MFI of each marker (CTLA-4, CD120b, and GITR)
was not different among CCR5+ versus CCR5− cells.
Among Tregs isolated from psoriasis patients, however,
no difference was observed in suppressive capacity between
CCR5+ Tregs versus Treg pooled cells (Fig. 3C). Therefore it
is not clear if decreased CCR5 expression is functionally
related to the suppressive defect or if it is one of the
phenotypic characteristics of the abnormal psoriatic Tregs.
3.3. Dermal Tregs express higher CCR5 levels in
healthy skin compared to psoriatic skin
Next we provide proof of concept demonstrating that CCR5+
Tregs in human psoriatic lesions versus CCR5+ Tregs elicited
into healthy control skin using sensitization and subsequent
challenge with the hapten di-nitrochlorobenzene (DNCB),
which ultimately self-resolves are less infiltrating. To avoid
the detection of effector T cells transiently expressing CD25,
epidermal and dermal cell suspensions were rested for 48 h
before flow cytometric analysis.
In vivo priming of normal skin with the 0.03% DNCB was
used to elicit a regulatory T cell response. Infiltrating Tregs
were obtained and compared to non-elicited (except by
psoriasis) Treg cells isolated from a psoriatic plaque. CCR5+
(compared to isotype) cells were then assessed for the
expression of Foxp3.
Interestingly, CD4+CD25high psoriatic Treg cells co-expressed
CCR5 in only 3.6% of Tregs cells, compared to 39.6% expression
in Foxp3+ Tregs cells recruited into healthy skin by hapten
elicitation (Fig. 4).
3.4. Chemotaxis of CCR5+-Tregs is reduced in
psoriatic patients
To determine if the expression of CCR5 affected the ability of
Treg cells to migrate, we examined the ability of CCR5+ Tregand protein FoxP3. A) Cumulative data (n = 5) demonstrate a
Treg cells compared to that of both pooled Treg and CCR5− Treg
mRNA levels compared to pooled Treg cells. B) Peripheral blood
h levels of CD25 were selected. CD4+CD25high T cells (black dots)
CR3] (right). CCR5 expression (MFI 45.2) showed a trend toward
ceptor CXCR3 (MFI: 51.4) in Tregs showed no relative increase in
Figure 3 Control CCR5+ Treg cells are functionally high potency
regulatory T cells in normal yet still dysfunctional in psoriasis
Tregs. A) Cumulative data demonstrate a statistically significant
enhancement of suppressive function of Treg cells when we
compare CCR5+ Treg cells to the Treg cell-pool at any ratio
ranging from 1:1 to 1:4 (p b 0.05). B) Control CCR5+ Tregs showed
increased suppressive capabilities compared to pooled Tregs. C)
Psoriatic CCR5+ or pooled Tregs display decreased suppressive
capacity compared to normal control Tregs. Furthermore, no
increased suppressive capacity was observed for CCR5+ psoriatic
Treg cells compared to pooled Tregs. Black and white bars
represent CCR5+ Treg or pooled Tregs respectively.
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to migrate toward known ligands of the CCR5 receptor such
MIP-1β and RANTES. 1 × 105 CCR5+ peripheral Tregs from
psoriatic patients or healthy donors were loaded onto the
upper transwell plates. The average number of CCR5+ Treg
cells isolated from healthy controls that migrated toward
MIP-1β or RANTES was 12.4 × 103 ± 3.2%, and 19.8 × 103 ±
2.1% (p b 0.05), respectively, whereas CCR5+ Treg cellsisolated from psoriatic individuals (open bars) showed
significantly weaker chemotaxis to both MIP-1β and RANTES
(4.3 × 103 ± 1.7%, and 7.7 × 103 ± 2.2%, thousand cells,
respectively, n = 4, p b 0.01), (Fig. 5).4. Discussion
Psoriasis is currently interpreted to be an inflammatory skin
disease that has been demonstrated to be driven by T cells
[23,24]. The psoriatic pathology is a unique source of cutaneous
T cells and can provide valuable information regarding the
interaction of regulatory T cells (Treg) with pathogenic effector
T cells (Teff) in vivo.
CCR5 is a G-Protein Coupled Receptor (GPCR) known to be a
co-receptor for HIV during infection of helper T-cells that aids
the virus to establish a chronic infection. CCR5 is expressed
on myeloid as well as lymphoid cells, including monocytes,
macrophages, dendritic cells and T-cells [25,26]. However, its
relevance in skin homing and its function in human Tregs has
not been described in detail. Importantly, CCR5+ Treg cells
have been experimentally shown in the periphery to limit Th1
immune responses in murine inflammatory disease models
including Leishmania major infection [27] and acute
graft-versus-host disease [28,29]. Interestingly, a randomized
placebo controlled trial on psoriasis patients treated with the
CCR5 inhibitor SCH351125 was recently performed [30]. This
study found no statistically significant clinical improvement in
psoriasis patients treated with the CCR5 inhibitor (50 mg
twice daily, orally for 28 days) over a follow-up period of
4 weeks. Interestingly, this study did report that relative
expression of CCR5 in proportion to the cells observed showed
only a statistically significant difference between lesional and
non-lesional CD3 cells in the epidermis. These observations
suggest that therapeutics targeting CCR5 are not likely to
reverse established disease but rather may be a preventive
measure.
In the present study, we sought to assess the expression
levels of CCR5 specifically on Tregs involved in psoriatic
pathology. We provide evidence that the CCR5+ subset of
CD4+CD25high Tregs was associated with increased suppres-
sion of T effector cells in healthy control individuals.
Accordingly, we also demonstrate that CCR5+ Tregs express
higher levels of Foxp3 mRNA as well as Foxp3 protein
(Figs. 2A and B). However, we do not believe that CCR5 itself
leads to increased Treg function. We show that peripheral
psoriatic Tregs express lower CCR5 levels compared to Tregs
isolated from healthy controls (Fig. 1). Further, we show
that psoriatic Treg cells expressing CCR5 are still function-
ally deficient in suppression.
We have also demonstrated that skin-infiltrating psoriatic
Foxp3+ Tregs express lower levels of CCR5 on their surface
compared to Treg cells elicited in healthy skin in response
to a contact sensitizing agent elicitation (~4% compared to
~40%) in CCR5+ expression on Tregs (Fig. 4). In the latter
situation, DNCB elicitation provokes a self-resolving skin
inflammatory condition over the course of approximately
10 days total time, whereas psoriasis skin represents an
ongoing non-self-resolving inflammatory site. This differ-
ence in resolution may alter the timing of CCR5 expression or
the micromilieu of the resolving lesion may differ from a
non-resolving site such that recruitment of cells with varying
Figure 4 Skin-infiltrating FoxP3+ Treg cells showed less CCR5 expression in psoriasis patient. Dermal cells were extracted from both
0.03% DNCB elicited healthy control skin and psoriatic lesional skin, and analyzed for CCR5 expression levels on skin-infiltrating Treg
cells using flow cytometry. A) In a representative experiment, approximately 40% of Treg cells isolated from healthy skin undergoing
DNCB elicited inflammation expressed CCR5, psoriatic Treg cells exhibited approximately 10 times less expression (4%) of
CCR5-expressing regulatory cells. B) MFI of CCR5-expressing cells among total skin-infiltrating Tregs is represented in black in the
x-axis. Isotype controls are shown in white. (This was a one-time pilot observational experiment, therefore n = 1).
Figure 5 Psoriatic CCR5+ Treg cells showed less migratory
capacity toward CCR5 ligands. Chemotaxis assay using transwell
plates was conducted in vitro, and the migratory capacity of both
control and psoriatic CCR5+ Treg cells toward the CCR5 relevant
chemokines MIP-1β and RANTES was determined. Average cell
counts of control CCR5+ Treg cells migrated toward MIP-1β and
RANTES were 12.4 and 19.8 × 103 cells, respectively, whereas
psoriatic CCR5+ Treg cells (open bars) showed significantly weaker
chemotactic responses to both MIP-1β and RANTES (4.3 and
7.7 × 103 cells, respectively, n = 4).
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sites in a time dependent manner. For example, an acute
inflammatory burst, such as that observed in a sensitization
response may produce a cytokine gradient that attracts
Treg cells expressing higher CCR5 levels. In contrast, a
chronic inflammatory state, such as that of psoriasis skin
may recruit Treg cells that have lower CCR5 expression. This
could suggest that in psoriasis, FoxP3 expression becomes
decoupled and does not correlate with CCR5 expression
(Fig. 4 right top panel), compared to controls (Fig. 4 left top
panel). Because wound-healing responses are not generally
different in psoriasis patients, the acute skin milieu may still
be capable of eliciting CCR5high Tregs, however the chronic
tissue cytokine/chemokine micromileu does not appear to
recruit these cells under static conditions. Chemotactic
studies using the CCR5 ligands MIP-1β and RANTES confirmed
that the psoriatic Tregs exhibit a decreased migratory
potential to either chemokine, known to be produced in
psoriasis skin [31–33] compared to the increased migratory
capacity of Tregs from healthy controls (Fig. 5).
These results suggest a possible mechanistic explanation for
dysfunction of the suppressive capacity of psoriatic Treg cells
compared to healthy Treg potential for controlling effector T
cell proliferation competently [18]. One possible explanation is
that lower CCR5 levels may be responsible for the psoriatic
Tregs decreased homing toward inflammatory signals (such as
RANTES and MIPβ) released by the psoriatic plaques. Further-
more, the lower levels of Foxp3+ in CCR5+ psoriatic Tregs could
contribute to the inability of psoriatic Tregs to sufficiently
117CCR5+ T reg cellssuppress pathogenic effector T cell expansion within psoriatic
plaques. The inability of psoriatic Tregs to act may lead to a
plaque microenvironment wherein the psoriatic milieu biases
effector or even regulatory T cells toward becoming patho-
genic (Th17) cell types as described recently [34].
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.clim.2013.06.007.
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